Trial Profile
Phase II study with oral fibroblast growth factor-1 inhibitor BIBF1120 as second line treatment in lung carcinoma patients harboring fibroblast growth factor receptor-1 gene amplification (NVALT15)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NVALT15
- 17 Mar 2019 This trial has been discontinued in Spain.
- 11 Jul 2014 New trial record